by MM360 Staff | Apr 28, 2025 | Uncategorized
Source: CureToday articles TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. Read More
by MM360 Staff | Apr 28, 2025 | Uncategorized
Source: CureToday articles Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer. Read More
by MM360 Staff | Apr 28, 2025 | Uncategorized
Source: CureToday articles Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population. Read More
by MM360 Staff | Apr 27, 2025 | Uncategorized
Source: CureToday articles HT-KIT, a novel targeted therapy for GIST, demonstrated the ability to reduce tumor burden in humanized mouse models and induce tumor cell death. Read More
by MM360 Staff | Apr 27, 2025 | Uncategorized
Source: CureToday articles Reflecting upon my relationship with Jill over the past 25 years, I am in awe of all she has accomplished. Read More
by MM360 Staff | Apr 26, 2025 | Uncategorized
Source: CureToday articles Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025. Read More